For instance, the RECOVERY trial found no significant benefits from low-titer CP, while a separate study from Argentina reported a 48% reduction in severe respiratory disease among elderly patients receiving high-titer CP shortly after symptom onset [15, 16]. Here, CP is linked to respiratory system disorder.